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Initial indications that retroviruses are connected to neoplastic transformation were
seen more than a century ago. This concept has also been tested for endogenized
retroviruses (ERVs) that are abundantly expressed in many transformed cells. In healthy
cells, ERV expression is commonly prevented by DNA methylation and other epigenetic
control mechanisms. ERVs are remnants of former exogenous forms that invaded the
germ line of the host and have since been vertically transmitted. Several examples
of ERV-induced genomic recombination events and dysregulation of cellular genes
that contribute to tumor formation have been well documented. Moreover, evidence is
accumulating that certain ERV proteins have oncogenic properties. In contrast to these
implications for supporting cancer induction, a recent string of papers has described
favorable outcomes of increasing human ERV (HERV) RNA and DNA abundance by
treatment of cancer cells with methyltransferase inhibitors. Analogous to an infecting
agent, the ERV-derived nucleic acids are sensed in the cytoplasm and activate innate
immune responses that drive the tumor cell into apoptosis. This “viral mimicry” induced
by epigenetic drugs might offer novel therapeutic approaches to help target cancer
cells that are normally difficult to treat using standard chemotherapy. In this review, we
discuss both the detrimental and the new beneficial role of HERV reactivation in terms
of its implications for cancer.
Keywords: human endogenous retrovirus (HERV), HERV, HERV-K, cancer, innate sensing, DNA-methylation, viral
mimicry
INTRODUCTION
Scattered throughout the genomes of all vertebrates are millions of footprints from past invasion
events by retroelements; i.e., fragments of genomic DNA that have been retrotranscribed from
RNA. Indeed, 43% of the human genome is made up of such elements and 8% of the genome
is comprised of retroviruses that infected human ancestors, entering cells of the germ line or
proliferating thereafter by retrotransposition (Katzourakis et al., 2005). This “retroviral self ” can
be classified into more than 30 distinct HERV families (Bannert and Kurth, 2004). By now, all
of the known proviral sequences in the human germ line have suffered postinsertional mutations
and deletions and have lost the ability to produce replication competent viral particles. However,
around 100 of the germ line invaders belonging to the most recently active HERV-K(HML-2)
family are full-length (or nearly) (Figure 1A). Many of the most recently acquired elements are
polymorphic, leading to a diversity of haplotypes in the human population. HERV-K113, for
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FIGURE 1 | Genomic organization of HERV-K(HML-2) and proposed role of HERVs in tumorigenesis. (A) Schematic depiction of the HERV-K(HML-2) provirus.
(B) Presumed cancer promoting implications of HERVs at the DNA level. (i) Recombination event leading to an LTR-driven expression of exons of a potential
oncogene. (ii) LTR-driven expression of a nearby proto-oncogene. Exons are shown in green and the cellular promotor in blue. (C) Potential cancer-promoting effects
by HERV-encoded proteins Env (i) and Rec/Np9 (ii). Aberrant signal transduction leading to transformation of the cell is indicated by a lightning sign. Binding of Rec
or Np9 to PLZF prevents PLZF from functionally inhibiting c-MYC. Interaction of Rec with TZFP or hSGT has been suggested to abrogate inhibition of the androgen
receptor by these two cellular proteins. Interaction of Np9 with LNX activates the LNX/Numb/Notch pathway.
example, a well-studied non-infectious full-length provirus with
open reading frames, is present in only about 30% of Africans and
12% of individuals from other parts of the world. It is becoming
increasingly evident that differences in our personal “HERVome”
heritage can influence individual traits and susceptibility to
disease.
This is particularly obvious with regard to the impact of
retroviral promoters, splice sites and other regulatory elements
on the expression of proteins and non-coding RNAs. Retroviral
LTRs are bona fide promotors able to initiate transcription if
appropriate transcription factors are present in the nucleus and
their access to the LTR is not epigenetically restricted. Under
such conditions, mRNAs are produced that occasionally encode
functional viral proteins, and in the case of HERV-K(HML-2),
non-infectious viral particles are in fact released (Boller et al.,
1983). In differentiated healthy cells, however, LTR activity
is tightly repressed by epigenetic constraints such as DNA
methylation. In contrast, silencing in embryonic stem cells
depends primarily on the activity of histone methyltransferases
and other histone modifications (Rowe and Trono, 2011).
Transcription of retroviral LTRs plays a fundamental role in the
maintenance of pluripotency and induction of an antiviral state
in those cells (Grow et al., 2015). The physiological role of HERV
expression in embryonic stem cells is not the only known example
of domestication of these genomic parasites to serve the host,
i.e., “exaptation.” The best known examples in this regard are the
syncytin genes: HERV envelope proteins under positive selection
that play an important role in the physiology of the placenta in
mammals (Dupressoir et al., 2012; Lavialle et al., 2013).
Conversely, since the early days of HERV research, these
elements have been implicated in cellular transformation
processes associated to various types of cancer, although recent
studies suggest that expression of HERV-derived nucleic acids
may also have a beneficial impact in the fight against cancer.
Implications of HERVs in the Promotion
of Transformation
Investigation on human retroviruses and their involvement in
cancerogenesis started in the early 1970s with the search for
reverse transcriptase activity and virus particles in tumor cells
(Sarngadharan et al., 1972; Zhdanov et al., 1973). This search
was later extended to retroviral sequences derived from or related
to murine retroviruses in the human genome, as several murine
retroviruses are established transforming agents (Chumakov
et al., 1982; Repaske et al., 1983).
There is a plethora of publications reporting HERV activation
in various cancers: breast cancer (Wang-Johanning et al., 2001,
2003, 2008; Burmeister et al., 2004; Contreras-Galindo et al.,
2008; Golan et al., 2008; Zhou et al., 2016; Johanning et al., 2017),
lymphoma (Contreras-Galindo et al., 2008; Maliniemi et al.,
2013; Fava et al., 2016), melanoma (Muster et al., 2003; Buscher
et al., 2005; Hirschl et al., 2007; Serafino et al., 2009; Reiche
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et al., 2010; Stengel et al., 2010; Huang et al., 2013; Singh et al.,
2013), ovarian cancers (Gotzinger et al., 1996; Wang-Johanning
et al., 2007; Iramaneerat et al., 2011; Heidmann et al., 2017), and
prostate cancers (Tomlins et al., 2007; Ishida et al., 2008; Goering
et al., 2011; Agoni et al., 2013; Goering et al., 2015). However,
to date, there is no conclusive picture emerging regarding the
role and impact of HERVs as causative or promoting agents in
cancerogenesis, although some well-described examples of links
at the DNA and protein levels are known.
At the DNA Level
Non-allelic recombination of HERV sequences can lead to
deletions, duplications, and other chromosomal rearrangements
(Figure 1B). In some prostate cancer cases, a translocation
of the HERV-K_22q11.23 5′-LTR-UTR sequence upstream of
the transcription factor ETS translocation variant 1 (ETV1)
has been described, which results in the enhanced expression
of the ETV1 oncogene promoting cancerogenesis (Tomlins
et al., 2007). LTRs can also act as alternative promotors
and dysregulate nearby proto-oncogenes, or growth-promoting
cellular genes (Figure 1B). For example, it was shown in B
cell-derived Hodgkin’s lymphoma cells that transcription of the
proto-oncogene colony-stimulating factor 1 receptor (CSF1R)
is driven by an aberrantly activated LTR promoter of the
THE1B retrotransposon, an apparent member of the mammalian
LTR retrotransposons (MaLR) family (Lamprecht et al., 2010).
Moreover, in the same study, it could also be demonstrated that
the derepression of THE1B LTR in those Hodgkin’s lymphoma
cells is a consequence of the loss of transcriptional corepressor
CBFA2T3 expression, which leads to disturbed epigenetic control
(Lamprecht et al., 2010). A very recent review summarizes several
studies addressing the impact of HERV LTR on cellular genes,
among other effects (Kassiotis and Stoye, 2017).
At the Protein Level
Unlike HTLV-1 and the tax protein, HERVs do not possess a bona
fide oncogene. However, expression of some HERV Env proteins
may also be detrimental due to its ability to induce cell–cell
fusion and may contribute by this way or others to tumorigenesis
(Duelli and Lazebnik, 2003; Bjerregaard et al., 2006). In in vitro
experiments, an Env protein coded by the HERV-K(HML-2)
consensus sequences as well as by several HERV-K(HML-2)
elements can interact with a cellular signaling pathway often
involved in cancers (Lemaitre et al., 2017), suggesting a potential
pro-oncogenic role of these HERV Envs (Figure 1C). Another
potential effect of HERV Env expression might be the promotion
of tumor escape through immune modulation, mediated by the
immunosuppressive domain contained in the transmembrane
region (Mangeney et al., 2001, 2005; Kudo-Saito et al., 2014).
Moreover, the expression of the HERV-K(HML-2) accessory
proteins Rec and Np9 (Magin et al., 1999; Armbruester et al.,
2002) can be linked to tumorigenesis (Galli et al., 2005; Chen
et al., 2013; Schmitt et al., 2013; Singh et al., 2013; Fischer
et al., 2014). Paradoxically, transcripts of rec and np9 from
different HERV-K(HML-2) loci appear to be present in various
normal human tissues (Schmitt et al., 2015). It is known that Rec
and Np9 both interact with the cellular promyelocytic leukemia
zinc-finger protein (PLZF) (Boese et al., 2000; Denne et al.,
2007), a transcriptional repressor of the c-MYC proto-oncogene.
Furthermore, Rec also binds to the testicular zinc-finger protein
(TZFP) (Kaufmann et al., 2010) and the human small glutamine-
rich tetratricopeptide repeat protein (hSGT) (Hanke et al., 2013),
both involved in androgen receptor repression (Figure 1C).
Rec-driven dysregulation of the androgen receptor signaling
may eventually result in tumor induction or promotion (Hanke
et al., 2013). In addition to PLZF, Np9 also binds the ligand
of Numb protein X (LNX) and is therefore interacting with
the Numb/Notch signaling cascade (Armbruester et al., 2004).
Dysregulation of this pathway has been linked to several cancers
(Roy et al., 2007; Downey et al., 2015).
HERV Expression as a Diagnostic Marker
for Tumors
The significantly elevated expression of various HERV elements
in cancer cells has spurred studies for their use as biomarkers
for malignant transformation, staging, and prognosis of cancers
(Harzmann et al., 1982; Hahn et al., 2008; Wallace et al., 2014;
Perot et al., 2015; Ma et al., 2016). One of the best candidates
for diagnostic purpose in this regard is the HERV-K(HML-2)
envelope protein in human breast cancer. Zhao et al. (2011)
demonstrated that this gene is expressed in the majority of breast
cancers from United States or Chinese women but generally
not expressed or at very low levels in normal breast tissue.
They subsequently showed that HERV-K(HML-2) antibodies and
mRNA are elevated in blood of patients at an early stage of
this cancer type, and further increase in patients who are at
risk of developing metastatis (Wang-Johanning et al., 2014).
Thus, screening for HERV-K(HML-2) expression seems to be
a promising additional option for early detection in women at
increased risk for breast cancer.
Antitumor Activity of HERVs
In many respects, an endogenous retrovirus is an intermediate
between a genuine virus and a regular human gene. This also
applies to the immune response directed against HERV-derived
nucleic acids and proteins.
Adaptive Immunity
Immunologic tolerance to HERV-derived proteins and peptides is
imperfect. This is presumably due to the tight epigenetic silencing
in the thymus and bone marrow that prevents normal deletion
of all reactive HERV-specific T and B lymphocytes, respectively.
Indeed, immunization of non-human primates with endogenous
retrovirus-derived antigens elicits robust polyfunctional T cell
responses and high antibody titers (Sacha et al., 2012; Sheppard
et al., 2014). In line with these findings, Boller et al. (1997) were
among the first to report transient HERV-K(HML-2)-specific
antibodies in the plasma of testicular cancer patients that became
rapidly undetectable following tumor surgery. Strong CTL
responses against epitopes of certain HERV proteins, considered
to be another class of tumor-specific antigens, have been found
in patients with various types of cancers (Schiavetti et al., 2002;
Mullins and Linnebacher, 2012; Rycaj et al., 2015). Although
evidence for tumor regression by the action of HERV-specific
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CTLs exists, the general impact of these antigens on the adaptive
antitumoral defense remains largely unclear (Huang et al., 1996;
Takahashi et al., 2008). This also holds true for the potential use of
tumor-specific HERV-based therapeutic vaccines against various
types of cancers.
Innate Immunity
The nucleic acids derived from endogenous retroviruses in the
cytoplasm and other cellular compartments do not escape a
response from the innate immune system. Although there are
marked differences between the innate immunity of humans
and mice, similar principles might act during the control of
ERV reactivation and innate sensing. In an elegant study in
a mouse model, Yu et al. (2012) have shown that Toll-Like
Receptors (TLRs) 3, 7, and 9 are essential for the control of
ERVs at least in mice. Mice lacking these receptors develop
late-onset leukemia by insertional mutagenesis of reactivated
replicating ERVs (Yu et al., 2012). A key factor for the production
of anti-ERV antibodies was further attributed to TLR7 thereby
linking innate and adaptive immunity (Figure 2). Similar to
TLR-knockout mice, those with inactivating mutations in the
maintenance gene DNA methyltransferase 1 (DNMT1) develop
tumors induced by reactivation of replication-competent ERVs
(Howard et al., 2008). Significant DNA hypomethylation and
ERV activation can also be achieved by treatment with DNA
methyltransferase inhibitors (DNMTis), such as 5-azacytidine
(Aza) and 5-aza-2′-deoxycytidine (Dac) (Stengel et al., 2010),
both of which are approved by the FDA for the treatment
of myelodysplastic syndromes (Kaminskas et al., 2005). These
inhibitors were initially thought to epigenetically reactivate
silenced tumor suppressor genes in malignant cells and render
these cells therefore more prone to apoptosis, but it is also
recognized that DNMTis induce immune responses against
cancer cells. Chiappinelli et al. (2015) and Roulois et al. (2015)
demonstrated a link between DNMTi-induced activation of
HERV expression and innate sensing of transcribed viral RNAs
and activation of innate immunity signaling pathways leading
to an inhibition of tumor cell growth. These results represent
a paradigm shift in our comprehension of the antitumor
activity of demethylating agents. The authors demonstrated
that DNMTis induce HERV-derived dsRNAs that are sensed
primarily by TLR3 (localized at the endosomal membrane)
and by the cytosolic CARD-domain family protein MDA5, a
known pattern recognition receptor. Following dsRNA binding,
the CARD domain of MDA5 interacts with the mitochondrial
antiviral signaling protein MAVS located on mitochondrial
membranes. This leads to the activation of NF-kB and the
phosphorylation and nuclear import of IRF7 resulting in a
profound interferon (IFN) response (Figure 2). TLR3 binding
to dsRNAs of endogenous origin also leads to both IRF and
NF-kB activation. In these experiments, Aza treatment also
induced partial demethylation of the IRF7 gene and increased its
expression. Due to the slow response toward DNMTi treatment,
the type I IFN response and thereby IFN release and activation
FIGURE 2 | Antitumor activity mediated by innate sensing of HERV RNA and DNA. Treatment of cancer cells with DNMTis results in demethylation of the LTR
promotors and HERV transcription. Viral nucleic acids in the cytoplasm and other cellular compartments (viral mimicry) are sensed by TLRs and other innate sensors
including MDA5. Upon activation these pattern recognition receptors initiate signal transduction pathways that result in production of type I and III IFNs and
pro-inflammatory cytokines further leading to promotion of an adaptive immune response (e.g., anti-HERV antibodies).
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of numerous IFN Stimulated Genes (ISGs) are delayed and
peak about 1 week after treatment (Chiappinelli et al., 2015).
Interestingly, while in the ovarian cancer cell model, the
outcome of a low dose Aza treatment was dominated by
an IFN I response (Chiappinelli et al., 2015; Stone et al.,
2017), in colorectal cancer cells, activated IFN III genes were
more preponderant (Roulois et al., 2015). The latter group
also demonstrated that cancer initiating cells, defined by
their ability to self-renew and difficult to reach by standard
chemotherapy, were importantly targeted by treatment. The
overall outcome of the innate immune response was a
suppression of tumor cell proliferation and enhanced apoptosis.
Moreover, Aza administration sensitized murine melanoma
cells to anti-CTLA-4 treatment and high expression of ISGs
correlated with a sustained clinical response to anti-CTLA-
4. A treatment combining DNMTis and immune checkpoint
inhibitors (e.g., anti-CTLA-4) is therefore regarded as extremely
promising. Supplementation with vitamin C was also suggested
to increase the effect of the DNMTis and was shown to
be effective (Liu et al., 2016). Vitamin C promotes DNA
demethylation through increased activity of the three so-called
“Ten-Eleven Translocation (TET)” enzymes, which convert 5-
methylcytosine to 5-hydroxymethylcytosine (Tahiliani et al.,
2009).
The induction of immune responses by unleashing ERV
expression from epigenetic restrictions has been termed “viral
mimicry,” i.e., a cellular response similar to those seen after
infection with an exogenous virus (Figure 2). Results from
these studies using Aza treatment have been corroborated by
others in different settings (Nicholas et al., 2017). In one of
these studies, a 3D culture system of intestinal mice tumors was
used to demonstrate that DNMT knockdown by Aza treatment
significantly reduced cell proliferation in tumor organoids (Saito
et al., 2016). More recently, the anticancer agent, RRx-001, a
dinitroazetidine derivate that is currently tested in phase II
clinical trials, has also been shown to elicit an IFN response
through epigenetic induction of viral mimicry. The remarkable
safety profile of this immunomodulatory anticancer agent makes
it a leading candidate for future clinical applications (Zhao et al.,
2017).
Although reactivated endogenous elements have been roughly
categorized at the family level, the actual chromosomal loci
remained unknown. The identification of these loci might help
to better understand epigenetic changes and cancer-specific
differences. In this context, it might also explain the surprisingly
frequent occurrence of bidirectional transcription in many ERVs
which appears to be the underlying reason for the strong
activation of MDA5, as this innate sensor requires extended
dsRNA structures for efficient activation (Mu et al., 2016).
There are many additional options for the enhancement and
advancement of an ERV-mediated epigenetic cancer therapy.
One approach might be the inhibition of dsRNA or DNA
degradation in cancer cells by blocking the activity of the
respective nucleases. Such an accumulation of ERV nucleic acids
has been reported in cells from individuals bearing inactivating
mutations in nucleases that normally clear nucleic acid from
the cytoplasm or influence their metabolism in the cytoplasm.
The most prominent examples are mutations in Three-prime
Repair Exonuclease 1 (TREX1) or Sam domain and HD domain
1 (SAMHD1), that are associated with the rare autoinflammatory
disease Aicardi-Goutieres syndrome (AGS) characterized by an
exaggerated type I IFN response (van Montfoort et al., 2014).
CONCLUSION
It has been recognized for many years that endogenous
retroviruses and other retroelements contribute to malignant
diseases as well as to inflammatory and autoimmune disorders
at the DNA and presumably at the protein level. However, until
recently, it escaped attention that an increased expression of
HERV-derived nucleic acids also has an adverse effect on cancer
cells and that this effect could be the basis of novel therapeutic
approaches. Importantly, targeting of the neoplastic cell will be
an important issue to prevent jumping from the “frying-pan”
into the fire. Aberrant reactivation and expression of HERVs in
healthy tissue not only bears the risk of new transformations
and autoimmune diseases, but also might influence cellular
physiology by activating HERV promotors that act on cellular
genes. Curing cancers by activating HERVs that instigate an
innate immune response is surely an appealing concept with high
expectations and is worth investing significant effort in the future.
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